Yahoo Finance Boston Scientific (BSX) DBS Programming Software Gets CE Mark
Boston Scientific, Inc. BSX recently obtained a CE Mark on the Vercise Neural Navigator 5 Software with STIMVIEW XT technology. When used as an element of the Vercise Genus Deep Brain Stimulation (DBS) Systems, it can provide clinicians with simple and actionable data for efficient programming to treat Parkinson’s disease, essential tremor and dystonia.
The latest development comes as a significant boost for the company’s Neuromodulation business. In July 2023, the software had received the FDA’s approval.
More on the News
The Vercise Neural Navigator 5 Software, featuring the STIMVIEW XT technology, is the newest addition to the fully integrated portfolio of image-guided programming solutions for Boston Scientific DBS Systems. Developed in partnership with leading software-driven medical technology company, Brainlab, these tools have demonstrated a 56% reduction in programming time and offer real-time visualization and stimulation of each person’s unique brain anatomy.
The software includes an improved user interface that displays patient data in a simplified format and gives clinicians access to advanced settings for increased therapy delivery. Its design enables more flexibility to better manage the evolving needs of individual patients at any stage of their condition.
Image Source: Zacks Investment Research
Boston Scientific focuses on creating tools that positively impact physicians and people with neurological conditions. The Vercise Neural Navigator 5 Software enhances the efficiency of DBS therapy, simplifying a usual time-consuming procedure. This enables hospitals and clinicians to free up capacity for more value-added tasks and improve patient care.
Industry Prospects
Per a research report, the DBS devices market was valued at $1.18 billion in 2022 and is expected to witness a CAGR of 9.9% by 2030.
Some key factors fueling the market growth include the rising geriatric population, the introduction of technologically advanced products, growing product demand as add-on therapy, rising incidence of chronic diseases, such as migraine and epilepsy, and the presence of highly unmet medical needs in these disease segments.
Progress in the Neuromodulation Business
In the first quarter of 2024, Neuromodulation sales grew 10% operationally, including high-single digits growth in the brain franchise. The addition of Relievant Medsystems, Inc. has been impactful, with the business continuing to perform well through steady expansion of payer coverage. Sales from its novel Intracept procedure are likely to witness a 50% uptick in 2024.
Furthermore, Boston Scientific received the FDA’s approval for an expanded indication of the WaveWriter SCS Systems for treating non-surgical back pain. The expanded indication is backed by positive one-year data from the SOLIS (SCS as an Option for Chronic Low Back and/or Leg Pain Instead of Surgery) randomized control trial. Per the late-breaking data, 90% of patients treated with the WaveWriter SCS reported significant pain relief of 50% or greater at three-month intervals. At one year, 84% of patients treated with the WaveWriter Systems reported 50% or greater pain relief and improved participation in daily activities, with a mean 25-point reduction in disability as measured by the Oswestry Disability Index.
Price Performance
In the past year, Boston Scientific shares have risen 44.9% against the industry’s decline of 1.8%.
Zacks Rank and Key Picks
Boston Scientific currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hims & Hers Health HIMS, ResMed RMD and Medpace MEDP. While Hims & Hers Health sports a Zacks Rank #1 (Strong Buy), ResMed and Medpace carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks Rank #1 stocks here.
Hims & Hers Heath shares have surged 181.7% in the past year. Estimates for the company’s earnings have increased from 18 cents to 19 cents in 2024 and from 33 cents to 35 cents in 2025 in the past 30 days.
HIMS’ earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for ResMed’s fiscal 2024 earnings per share have remained constant at $7.70 in the past 30 days. Shares of the company have plunged 14.3% in the past year compared with the industry’s decline of 1.8%.
RMD’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.
Estimates for Medpace’s 2024 earnings per share have remained constant at $11.29 in the past 30 days. Shares of the company have surged 81% in the past year compared with the industry’s 6.1% growth.
MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
ResMed Inc. (RMD) : Free Stock Analysis Report
Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report
Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report
